Jia Qingmei, Bowen Richard, Lee Bai-Yu, Dillon Barbara Jane, Masleša-Galić Saša, Horwitz Marcus A
Division of Infectious Diseases, Department of Medicine, 37-121 Center for Health Sciences, School of Medicine, University of California - Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1688, United States.
Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, United States.
Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.
A safer and more effective vaccine than the unlicensed Francisella tularensis Live Vaccine Strain (LVS) is needed to protect against the biowarfare agent F. tularensis. Previously, we developed an LVS ΔcapB mutant that is significantly safer than LVS and provides potent protective immunity against F. tularensis respiratory challenge when administered intranasally but limited protection when administered intradermally unless as part of a prime-boost vaccination strategy. To improve the immunogenicity and efficacy of LVS ΔcapB, we developed recombinant LVS ΔcapB (rLVS ΔcapB) strains overexpressing various F. tularensis Francisella Pathogenicity Island (FPI) proteins - IglA, IglB and IglC, and a fusion protein (IglABC) comprising immunodominant epitopes of IglA, IglB, and IglC downstream of different Francisella promoters, including the bacterioferritin (bfr) promoter. We show that rLVS ΔcapB/bfr-iglA, iglB, iglC, and iglABC express more IglA, IglB, IglC or IglABC than parental LVS ΔcapB in broth and in human macrophages, and stably express FPI proteins in macrophages and mice absent antibiotic selection. In response to IglC and heat-inactivated LVS, spleen cells from mice immunized intradermally with rLVS ΔcapB/bfr-iglC or bfr-iglABC secrete greater amounts of interferon-gamma and/or interleukin-17 than those from mice immunized with LVS ΔcapB, comparable to those from LVS-immunized mice. Mice immunized with rLVS ΔcapB/bfr-iglA, iglB, iglC or iglABC produce serum antibodies at levels similar to LVS-immunized mice. Mice immunized intradermally with rLVS ΔcapB/bfr-iglABC and challenged intranasally with virulent F. tularensis Schu S4 survive longer than sham- and LVS ΔcapB-immunized mice. Mice immunized intranasally with rLVS ΔcapB/bfr-iglABC - but not with LVS - just before or after respiratory challenge with F. tularensis Schu S4 are partially protected; protection is correlated with induction of a strong innate immune response. Thus, rLVS ΔcapB/bfr-iglABC shows improved immunogenicity and protective efficacy compared with parental LVS ΔcapB and, in contrast to LVS, has partial efficacy as immediate pre- and post-exposure prophylaxis.
需要一种比未经许可的土拉弗朗西斯菌活疫苗株(LVS)更安全、更有效的疫苗来预防生物战剂土拉弗朗西斯菌。此前,我们开发了一种LVS ΔcapB突变体,它比LVS安全得多,经鼻内给药时对土拉弗朗西斯菌呼吸道攻击能提供有效的保护性免疫,但经皮内给药时保护作用有限,除非作为初免-加强疫苗接种策略的一部分。为了提高LVS ΔcapB的免疫原性和效力,我们开发了重组LVS ΔcapB(rLVS ΔcapB)菌株,这些菌株过表达各种土拉弗朗西斯菌致病性岛(FPI)蛋白——IglA、IglB和IglC,以及一种融合蛋白(IglABC),该融合蛋白包含IglA、IglB和IglC的免疫显性表位,位于不同弗朗西斯菌启动子下游,包括细菌铁蛋白(bfr)启动子。我们发现,rLVS ΔcapB/bfr-iglA、iglB、iglC和iglABC在肉汤和人巨噬细胞中表达的IglA、IglB、IglC或IglABC比亲本LVS ΔcapB更多,并且在没有抗生素选择的情况下,在巨噬细胞和小鼠中稳定表达FPI蛋白。在用IglC和热灭活的LVS刺激后,经皮内用rLVS ΔcapB/bfr-iglC或bfr-iglABC免疫的小鼠的脾细胞分泌的干扰素-γ和/或白细胞介素-17比用LVS ΔcapB免疫的小鼠的脾细胞更多,与用LVS免疫的小鼠的脾细胞相当。用rLVS ΔcapB/bfr-iglA、iglB、iglC或iglABC免疫的小鼠产生的血清抗体水平与用LVS免疫的小鼠相似。经皮内用rLVS ΔcapB/bfr-iglABC免疫并经鼻内用强毒株土拉弗朗西斯菌Schu S4攻击的小鼠比假免疫和LVS ΔcapB免疫的小鼠存活时间更长。在用土拉弗朗西斯菌Schu S4进行呼吸道攻击之前或之后,经鼻内用rLVS ΔcapB/bfr-iglABC(而不是LVS)免疫的小鼠受到部分保护;这种保护与强烈的先天免疫反应的诱导相关。因此,与亲本LVS ΔcapB相比,rLVS ΔcapB/bfr-iglABC显示出改善的免疫原性和保护效力,并且与LVS不同,作为暴露前和暴露后即时预防有部分效力。